Cygenics (ASX: CYN) announce the first cystic fibrosis cord blood collection. Clinical history was made at The Mercy Hospital in Werribee on Easter Saturday, when baby Aiden Brundell donated his cord blood in the hope that his precious stem cells could one day rejuvenate sister Mikaela's lungs, which are failing from cystic fibrosis (CF), and save her life.
Clinical Cell Culture Ltd (ASX: CCE) today released its quarterly report, Appendix 4C, for the quarter ending 31 March 2006.
Clinical Cell Culture Ltd (ASX: CCE) today announced that Managing Director Troels Jordansen had indicated his intention to step down from his position as Chief Executive Officer by mutual agreement with the Board of Directors.
CyGenics Ltd. (ASX: CYN) announced its plans to establish a sound base in the European market to take advantage of exciting business opportunities in those markets. As a first step, CyGenics plans to acquire a significant stake in Dutch-based PharmaCell BV.
Life Therapeutics (ASX: LFE) announced today that it has reduced its total debt by A$4.5m (US$3.4m) following the conversion by Indus Capital of its remaining Tranche 1 Convertible Notes into 4,292,500 Life Therapeutic shares.
Clinical Cell Culture Ltd (ASX: CCE) announced that it had been informed by the Therapeutic Goods Administration (TGA) that its ReCell(R) tissue harvesting device had been recommended for approval in Australia.
Leading cell therapy services company CyGenics Ltd. (ASX: CYN) announced that its US-based subsidiary, Cytomatrix LLC, had been granted US Patent 6991933, Cell Culture Spinner Flasks. This patent adds to the five already granted to the CyGenics group. A number of other patents are pending.
